New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...
In a report released yesterday, Charlie CY Yang from Bank of America Securities maintained a Hold rating on Amgen (AMGN – Research Report), ...
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback